Pancreatic neuroendocrine tumor progression and resistance to everolimus: the crucial role of NF-kB and STAT3 interplay

Crocin Inhibits Angiogenesis and Metastasis in Colon Cancer via TNF-α/NF-kB/VEGF Pathways

(2022) Hamid A. Bakshi et al.   Cells

Targeting STAT3 by a small molecule suppresses pancreatic cancer progression

(2021) Huang Chen et al.   ONCOGENE

Inflammation-related cytokines and their roles in gastroenteropancreatic neuroendocrine neoplasms

(2020) Davorka Herman Mahečić et al.   Bosnian Journal of Basic Medical Sciences

A novel insight into the anticancer mechanism of metformin in pancreatic neuroendocrine tumor cells

(2020) E. Vitali et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

Metformin and Everolimus: A Promising Combination for Neuroendocrine Tumors Treatment

(2020) Eleonora Vitali et al.   Cancers

Lanreotide Induces Cytokine Modulation in Intestinal Neuroendocrine Tumors and Overcomes Resistance to Everolimus

(2020) Concetta Sciammarella et al.   Frontiers in Oncology

From microbiota toward gastro-enteropancreatic neuroendocrine neoplasms: Are we on the highway to hell?

(2020) Giovanni Vitale et al.   REVIEWS IN ENDOCRINE & METABOLIC DISORDERS

STAT3 Inhibition for Gastroenteropancreatic Neuroendocrine Tumors: Potential for a New Therapeutic Target?

(2019) Alexandra G. Lopez-Aguiar et al.   JOURNAL OF GASTROINTESTINAL SURGERY

The NF-KB pathway and endocrine therapy resistance in breast cancer

(2019) Phungern Khongthong et al.   ENDOCRINE-RELATED CANCER

Effects of novel somatostatin-dopamine chimeric drugs in 2D and 3D cell culture models of neuroendocrine tumors

(2019) Aura D Herrera-Martínez et al.   ENDOCRINE-RELATED CANCER

The 2019 WHO classification of tumours of the digestive system

(2019) Iris D. Nagtegaal et al.   HISTOPATHOLOGY

Gastroenteropancreatic neuroendocrine neoplasms and inflammation: A complex cross-talk with relevant clinical implications

(2019) Giovanni Vitale et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Everolimus in the treatment of neuroendocrine tumors: efficacy, side-effects, resistance, and factors affecting its place in the treatment sequence

(2018) Lingaku Lee et al.   EXPERT OPINION ON PHARMACOTHERAPY

Nuclear Factor-κB Promotes Urothelial Tumorigenesis and Cancer Progression via Cooperation with Androgen Receptor Signaling

(2018) Satoshi Inoue et al.   MOLECULAR CANCER THERAPEUTICS

Activation of mTOR/IκB-α/NF-κB pathway contributes to LPS-induced hypotension and inflammation in rats

(2017) Meryem Temiz-Resitoglu et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

FLNA is implicated in pulmonary neuroendocrine tumors aggressiveness and progression

(2017) Eleonora Vitali et al.   Oncotarget

Strong NFκB Expression is Associated With High-grade Dysplasia in Barrett’s Esophagus

(2017) Siraj M. El Jamal et al.   APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY

Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States

(2017) Arvind Dasari et al.   JAMA Oncology

Long-term acquired everolimus resistance in pancreatic neuroendocrine tumours can be overcome with novel PI3K-AKT-mTOR inhibitors

(2016) Timon Vandamme et al.   BRITISH JOURNAL OF CANCER

Filamin-A is required to mediate SST2 effects in pancreatic neuroendocrine tumours

(2016) Eleonora Vitali et al.   ENDOCRINE-RELATED CANCER

Systemic Therapies for Advanced Pancreatic Neuroendocrine Tumors

(2016) Nitya Raj et al.   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study

(2016) James C Yao et al.   LANCET

ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site

(2016) M. Pavel et al.   NEUROENDOCRINOLOGY

New Insights into the Role of Chronic Inflammation and Cytokines in the Etiopathogenesis of Gastroenteropancreatic Neuroendocrine Tumors

(2014) Maja Cigrovski Berkovic et al.   NEUROENDOCRINOLOGY

NF-κB-Induced IL-6 Ensures STAT3 Activation and Tumor Aggressiveness in Glioblastoma

(2013) Braden C. McFarland et al.   PLoS One

NF-κB and STAT3 signaling pathways collaboratively link inflammation to cancer

(2013) Yihui Fan et al.   Protein & Cell

Essential role of cooperative NF-κB and Stat3 recruitment to ICAM-1 intronic consensus elements in the regulation of radiation-induced invasion and migration in glioma

(2012) D Kesanakurti et al.   ONCOGENE

mTOR Activation in Well Differentiated Pancreatic Neuroendocrine Tumors: A Retrospective Study on 34 Cases

(2011) Chen-Fei Zhou et al.   HEPATO-GASTROENTEROLOGY

Everolimus for Advanced Pancreatic Neuroendocrine Tumors

(2011) James C. Yao et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nuclear factor κB transcription factors are coexpressed and convey a poor outcome in ovarian cancer

(2010) Christina M. Annunziata et al.   CANCER

The expression of IL-8 and IL-8 receptors in pancreatic adenocarcinomas and pancreatic neuroendocrine tumours

(2009) Farah Hussain et al.   CYTOKINE

Dangerous liaisons: STAT3 and NF-κB collaboration and crosstalk in cancer

(2009) Sergei I. Grivennikov et al.   CYTOKINE & GROWTH FACTOR REVIEWS

Akt-mediated regulation of NFκB and the essentialness of NFκB for the oncogenicity of PI3K and Akt

(2009) Dong Bai et al.   INTERNATIONAL JOURNAL OF CANCER

Pancreatic Endocrine Tumors: Expression Profiling Evidences a Role for AKT-mTOR Pathway

(2009) Edoardo Missiaglia et al.   JOURNAL OF CLINICAL ONCOLOGY

Spheroid-based drug screen: considerations and practical approach

(2009) Juergen Friedrich et al.   Nature Protocols

The Interleukin-8 Pathway in Cancer

(2008) D. J.J. Waugh et al.   CLINICAL CANCER RESEARCH